217 related articles for article (PubMed ID: 33682709)
1. Impacts of Iron Metabolism Dysregulation on Alzheimer's Disease.
Jouini N; Saied Z; Ben Sassi S; Nebli F; Messaoud T; Hentati F; Belal S
J Alzheimers Dis; 2021; 80(4):1439-1450. PubMed ID: 33682709
[TBL] [Abstract][Full Text] [Related]
2. Ceruloplasmin is increased in cerebrospinal fluid in Alzheimer's disease but not Parkinson's disease.
Loeffler DA; DeMaggio AJ; Juneau PL; Brickman CM; Mashour GA; Finkelman JH; Pomara N; LeWitt PA
Alzheimer Dis Assoc Disord; 1994; 8(3):190-7. PubMed ID: 7986488
[TBL] [Abstract][Full Text] [Related]
3. Effects of hemochromatosis and transferrin gene mutations on iron dyshomeostasis, liver dysfunction and on the risk of Alzheimer's disease.
Giambattistelli F; Bucossi S; Salustri C; Panetta V; Mariani S; Siotto M; Ventriglia M; Vernieri F; Dell'acqua ML; Cassetta E; Rossini PM; Squitti R
Neurobiol Aging; 2012 Aug; 33(8):1633-41. PubMed ID: 21514009
[TBL] [Abstract][Full Text] [Related]
4. A low-molecular-weight ferroxidase is increased in the CSF of sCJD cases: CSF ferroxidase and transferrin as diagnostic biomarkers for sCJD.
Haldar S; Beveridge 'J; Wong J; Singh A; Galimberti D; Borroni B; Zhu X; Blevins J; Greenlee J; Perry G; Mukhopadhyay CK; Schmotzer C; Singh N
Antioxid Redox Signal; 2013 Nov; 19(14):1662-75. PubMed ID: 23379482
[TBL] [Abstract][Full Text] [Related]
5. Features of ceruloplasmin in the cerebrospinal fluid of Alzheimer's disease patients.
Capo CR; Arciello M; Squitti R; Cassetta E; Rossini PM; Calabrese L; Rossi L
Biometals; 2008 Jun; 21(3):367-72. PubMed ID: 18060472
[TBL] [Abstract][Full Text] [Related]
6. Ceruloplasmin/Transferrin ratio changes in Alzheimer's disease.
Squitti R; Salustri C; Siotto M; Ventriglia M; Vernieri F; Lupoi D; Cassetta E; Rossini PM
Int J Alzheimers Dis; 2010 Dec; 2011():231595. PubMed ID: 21234401
[TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal fluid diagnostic markers correlate with lower plasma copper and ceruloplasmin in patients with Alzheimer's disease.
Kessler H; Pajonk FG; Meisser P; Schneider-Axmann T; Hoffmann KH; Supprian T; Herrmann W; Obeid R; Multhaup G; Falkai P; Bayer TA
J Neural Transm (Vienna); 2006 Nov; 113(11):1763-9. PubMed ID: 16736242
[TBL] [Abstract][Full Text] [Related]
8. [Ceruloplasmin activity and the iron-binding capacity of cerebrospinal fluid transferrin in infectious forms of syphilis].
Borisenko AM
Vestn Dermatol Venerol; 1973 Nov; 47(11):60-4. PubMed ID: 4779397
[No Abstract] [Full Text] [Related]
9. Isobaric Quantification of Cerebrospinal Fluid Amyloid-β Peptides in Alzheimer's Disease: C-Terminal Truncation Relates to Early Measures of Neurodegeneration.
Rogeberg M; Almdahl IS; Wettergreen M; Nilsson LN; Fladby T
J Proteome Res; 2015 Nov; 14(11):4834-43. PubMed ID: 26452689
[TBL] [Abstract][Full Text] [Related]
10. Social Networks and Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Pathology in Cognitively Intact Older Adults: The CABLE Study.
Ma YH; Wang YY; Tan L; Xu W; Shen XN; Wang HF; Hou XH; Cao XP; Bi YL; Dong Q; Yang JL; Yu JT
J Alzheimers Dis; 2021; 81(1):263-272. PubMed ID: 33749650
[TBL] [Abstract][Full Text] [Related]
11. Sugar chains of cerebrospinal fluid transferrin as a new biological marker of Alzheimer's disease.
Taniguchi M; Okayama Y; Hashimoto Y; Kitaura M; Jimbo D; Wakutani Y; Wada-Isoe K; Nakashima K; Akatsu H; Furukawa K; Arai H; Urakami K
Dement Geriatr Cogn Disord; 2008; 26(2):117-22. PubMed ID: 18654083
[TBL] [Abstract][Full Text] [Related]
12. Ceruloplasmin, a Potential Therapeutic Agent for Alzheimer's Disease.
Zhao YS; Zhang LH; Yu PP; Gou YJ; Zhao J; You LH; Wang ZY; Zheng X; Yan LJ; Yu P; Chang YZ
Antioxid Redox Signal; 2018 May; 28(14):1323-1337. PubMed ID: 28874056
[TBL] [Abstract][Full Text] [Related]
13. [Ceruloplasmin (Cp) and iron in connection with Parkinson's disease (PD) and Alzheimer's disease (AD)].
Johannesson T; Kristinsson J; Torsdottir G; Snaedal J
Laeknabladid; 2012 Oct; 98(10):531-7. PubMed ID: 23043066
[TBL] [Abstract][Full Text] [Related]
14. Plasma transferrin and hemopexin are associated with altered Aβ uptake and cognitive decline in Alzheimer's disease pathology.
Ashraf A; Ashton NJ; Chatterjee P; Goozee K; Shen K; Fripp J; Ames D; Rowe C; Masters CL; Villemagne V; Hye A; Martins RN; So PW;
Alzheimers Res Ther; 2020 Jun; 12(1):72. PubMed ID: 32517787
[TBL] [Abstract][Full Text] [Related]
15. Metal-score as a potential non-invasive diagnostic test for Alzheimer's disease.
Squitti R; Pasqualetti P; Polimanti R; Salustri C; Moffa F; Cassetta E; Lupoi D; Ventriglia M; Cortesi M; Siotto M; Vernieri F; Rossini PM
Curr Alzheimer Res; 2013 Feb; 10(2):191-8. PubMed ID: 23036026
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid levels of amyloid precursor protein and amyloid beta-peptide in Alzheimer's disease and major depression - inverse correlation with dementia severity.
Hock C; Golombowski S; Müller-Spahn F; Naser W; Beyreuther K; Mönning U; Schenk D; Vigo-Pelfrey C; Bush AM; Moir R; Tanzi RE; Growdon JH; Nitsch RM
Eur Neurol; 1998; 39(2):111-8. PubMed ID: 9520072
[TBL] [Abstract][Full Text] [Related]
17. Preanalytical approaches to improve recovery of amyloid-β peptides from CSF as measured by immunological or mass spectrometry-based assays.
Schauer SP; Mylott WR; Yuan M; Jenkins RG; Rodney Mathews W; Honigberg LA; Wildsmith KR
Alzheimers Res Ther; 2018 Nov; 10(1):118. PubMed ID: 30486870
[TBL] [Abstract][Full Text] [Related]
18. Cognitive impairment in late-life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid.
Forlenza OV; Aprahamian I; Radanovic M; Talib LL; Camargo MZ; Stella F; Machado-Vieira R; Gattaz WF
Bipolar Disord; 2016 Feb; 18(1):63-70. PubMed ID: 26876913
[TBL] [Abstract][Full Text] [Related]
19. Cerebrospinal fluid amyloid beta peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: indication of carrier-mediated epitope masking of amyloid beta peptides.
Bibl M; Esselmann H; Otto M; Lewczuk P; Cepek L; Rüther E; Kornhuber J; Wiltfang J
Electrophoresis; 2004 Sep; 25(17):2912-8. PubMed ID: 15349929
[TBL] [Abstract][Full Text] [Related]
20. Aminoterminally truncated and oxidized amyloid-β peptides in the cerebrospinal fluid of Alzheimer's disease patients.
Bibl M; Gallus M; Welge V; Esselmann H; Wiltfang J
J Alzheimers Dis; 2012; 29(4):809-16. PubMed ID: 22460324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
